奥扎格雷钠治疗出血性脑梗死的临床观察  

Study of Safety and Curative Effect of Ozagrel in Treatment of Hemorrhagic Infarction

作　　者：陈育华[1] 谢静[1] 马博[1] 钱卫东[1] 屈洪党[1] 

机构地区：[1]安徽省蚌埠医学院第一附属医院神经内科,233000

出　　处：《中华全科医学》2010年第11期1360-1361,共2页Chinese Journal of General Practice

摘　　要：目的探讨奥扎格雷钠治疗出血性脑梗死(HI)的临床疗效及安全性。方法将入选的39例HI患者随机分为奥扎格雷钠治疗组20例和对照组19例,治疗组予奥扎格雷80mg加入5%的葡萄糖水静脉滴注,2次/d,其他治疗同对照组。对照组给予中性治疗。两组治疗时间均为14d。各组治疗前后分别进行神经功能障碍评分及疗效分析,监测凝血功能和血小板。结果治疗期间两组患者均无再出血发生;治疗组无再梗死发生,对照组有2例再梗死发生;治疗组治疗后NIHSS均值低于对照组(P<0.05),总显效率和总有效率高于对照组(P<0.05)。结论奥扎格雷治疗HI是安全有效的。Objective To investigate safety and curative effect on ozagrel in treatment of hemorrhagic infarction.Methods 39 cases of patients with hemorrhagic infarction were randomly divided into two groups.In ozagrel group,20 patients were given 80 mg ozagrel and 250 ml physiological saline by intravenous injection twice every day for a period 14 days.The treatment for the rest was same with the control group.In control group,19 patients were given conventional therapy for a period 14 days.Before and after treatment,the neurological behavioral assessments were performed.PLT was also monitored.Results No patients developed rehaemorrhagia in two groups,no patients developed reinfarction in treatment group,but 2 cases in control group developed reinfarction during treatment.Total excellence rate and efficiency of treatment group were higher than that of the control group（P0.05）.NIHSS of treatment group after 14 days was lower than that of the control group（P0.05）.Conclusion The treatment of hemorrhagic infarction with ozagrel was safe and effective and can improve therapeutic effect in the near future.

关 键 词：脑梗死出血性转化 奥扎格雷钠 血小板 

分 类 号：R743.33[医药卫生—神经病学与精神病学]